Theresa M Carbonaro1, Matthew W Johnson1, Ethan Hurwitz1, Roland R Griffiths2,3. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823, USA. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823, USA. rgriff@jhmi.edu. 3. Department of Neuroscience, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823, USA. rgriff@jhmi.edu.
Abstract
RATIONALE: Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. OBJECTIVE: This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. METHODS: Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and placebo were administered under double-blind conditions to 20 healthy participants with histories of hallucinogen use. Instructions to participants and staff minimized expectancy effects. Various subjective, behavioral, and physiological effects were assessed after drug administration. RESULTS: High doses of both drugs produced similar increases in participant ratings of peak overall drug effect strength, with similar times to maximal effect and time-course. Psilocybin produced orderly dose-related increases on most participant-rated subjective measures previously shown sensitive to hallucinogens. DXM produced increases on most of these same measures. However, the high dose of psilocybin produced significantly greater and more diverse visual effects than DXM including greater movement and more frequent, brighter, distinctive, and complex (including textured and kaleidoscopic) images and visions. Compared to DXM, psilocybin also produced significantly greater mystical-type and psychologically insightful experiences and greater absorption in music. In contrast, DXM produced larger effects than psilocybin on measures of disembodiment, nausea/emesis, and light-headedness. Both drugs increased systolic blood pressure, heart rate, and pupil dilation and decreased psychomotor performance and balance. CONCLUSIONS:Psilocybin and DXM produced similar profiles of subjective experiences, with psilocybin producing relatively greater visual, mystical-type, insightful, and musical experiences, and DXM producing greater disembodiment.
RCT Entities:
RATIONALE: Although psilocybin and dextromethorphan (DXM) are hallucinogens, they have different receptor mechanisms of action and have not been directly compared. OBJECTIVE: This study compared subjective, behavioral, and physiological effects of psilocybin and dextromethorphan under conditions that minimized expectancy effects. METHODS: Single, acute oral doses of psilocybin (10, 20, 30 mg/70 kg), DXM (400 mg/70 kg), and placebo were administered under double-blind conditions to 20 healthy participants with histories of hallucinogen use. Instructions to participants and staff minimized expectancy effects. Various subjective, behavioral, and physiological effects were assessed after drug administration. RESULTS: High doses of both drugs produced similar increases in participant ratings of peak overall drug effect strength, with similar times to maximal effect and time-course. Psilocybin produced orderly dose-related increases on most participant-rated subjective measures previously shown sensitive to hallucinogens. DXM produced increases on most of these same measures. However, the high dose of psilocybin produced significantly greater and more diverse visual effects than DXM including greater movement and more frequent, brighter, distinctive, and complex (including textured and kaleidoscopic) images and visions. Compared to DXM, psilocybin also produced significantly greater mystical-type and psychologically insightful experiences and greater absorption in music. In contrast, DXM produced larger effects than psilocybin on measures of disembodiment, nausea/emesis, and light-headedness. Both drugs increased systolic blood pressure, heart rate, and pupil dilation and decreased psychomotor performance and balance. CONCLUSIONS:Psilocybin and DXM produced similar profiles of subjective experiences, with psilocybin producing relatively greater visual, mystical-type, insightful, and musical experiences, and DXM producing greater disembodiment.
Authors: José L Moreno; Terrell Holloway; Laura Albizu; Stuart C Sealfon; Javier González-Maeso Journal: Neurosci Lett Date: 2011-01-27 Impact factor: 3.046
Authors: Hannah K Delille; Judith M Becker; Sabrina Burkhardt; Barbara Bleher; Georg C Terstappen; Martin Schmidt; Axel H Meyer; Liliane Unger; Gerard J Marek; Mario Mezler Journal: Neuropharmacology Date: 2012-01-25 Impact factor: 5.250
Authors: Javier González-Maeso; Rosalind L Ang; Tony Yuen; Pokman Chan; Noelia V Weisstaub; Juan F López-Giménez; Mingming Zhou; Yuuya Okawa; Luis F Callado; Graeme Milligan; Jay A Gingrich; Marta Filizola; J Javier Meana; Stuart C Sealfon Journal: Nature Date: 2008-02-24 Impact factor: 49.962
Authors: André Schmidt; Michael Kometer; Rosilla Bachmann; Erich Seifritz; Franz Vollenweider Journal: Psychopharmacology (Berl) Date: 2012-07-27 Impact factor: 4.530
Authors: Michael M Schartner; Robin L Carhart-Harris; Adam B Barrett; Anil K Seth; Suresh D Muthukumaraswamy Journal: Sci Rep Date: 2017-04-19 Impact factor: 4.379
Authors: Frederick S Barrett; Theresa M Carbonaro; Ethan Hurwitz; Matthew W Johnson; Roland R Griffiths Journal: Psychopharmacology (Berl) Date: 2018-07-30 Impact factor: 4.530
Authors: Graham Blair; Corinne Wells; Ashley Ko; John Modarres; Caroline Pace; James M Davis; Amir H Rezvani; Jed E Rose; Edward D Levin Journal: Pharmacol Biochem Behav Date: 2020-04-01 Impact factor: 3.533
Authors: Manoj K Doss; Maxwell B Madden; Andrew Gaddis; Mary Beth Nebel; Roland R Griffiths; Brian N Mathur; Frederick S Barrett Journal: Brain Date: 2022-04-18 Impact factor: 15.255
Authors: John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane Journal: Front Psychiatry Date: 2021-12-17 Impact factor: 4.157
Authors: Albert Garcia-Romeu; Frederick S Barrett; Theresa M Carbonaro; Matthew W Johnson; Roland R Griffiths Journal: J Psychopharmacol Date: 2021-02-20 Impact factor: 4.153